Velgia^® continues the PROMOMED product line aimed at patients with metabolic diseases such as overweight, obesity and type 2 diabetes mellitus. Earlier, the Company launched the drug Quincenta®, intended for the treatment of diabetes mellitus and successfully replenished the missing Ozempik®.

Velgia^® developed by PROMOMED specifically for the treatment of obesity, it contains specially selected concentrations and increased dosages of the active substance, which increases its therapeutic effectiveness. The drug significantly reduces weight and helps to correct metabolic disorders that underlie the formation of a number of cardiovascular and oncological diseases - the main causes of death in our country.

The production technology of Velgia^® developed by the Company From the chemical synthesis of the substance to the finished, easy-to-use dosage form, it allows achieving the highest quality of the product and guarantees uninterrupted provision of patients with sought-after therapy. This is especially important given the chronic nature of the disease, the need for continuous treatment, and the widespread prevalence of obesity, which has the character of a non-communicable pandemic.

Semaglutide, the main active ingredient of the new drug Velgia^®, has a positive effect on most organs and systems. One drug, just once a week, and many positive effects — reducing the risks of vascular disorders, heart attacks and other heart diseases, reducing inflammation, improving cognitive function, improving reproductive function, beneficial effects on the emotional background, treatment of sleep apnea, prevention of type 2 diabetes, dementia, vascular aging, etc. In fact, this is a modern and scientifically proven anti-aging therapy that prolongs an active life and allows you to make the "medicine of the future" a real present.

Alexander Ametov, MD, Professor, Head of the Department of Endocrinology of the Russian Ministry of Health, UNESCO Network Chair on the topic "Bioethics of Diabetes Mellitus": "Obesity is a serious socially significant problem leading to a decrease in the quality of life and disability of the population and a significant increase in health system costs. The prevalence of obesity is growing at a gigantic pace. In our country alone, more than 44 million people are obese and need affordable, effective and safe therapy. The medical community welcomes the new achievements of Promomed aimed at restoring metabolic health. A new drug — Velgia^® "This is an example of providing our patients with the most modern therapy currently available and a big step in solving this important medical and social problem."

Ilya Bardin-Denisov, CEO of PROMOMED DM LLC: "Accessibility of innovative therapy for patients, their health, beauty and a happy life is the mission of our Company. Solving the problem of the obesity pandemic and reducing its burden has been our priority for many years. Creation and release of Velgia^® – This is a logical and natural step in the development of our line of overweight therapy drugs, and working closely with the country's leading endocrinologists allowed us to take this step as quickly as possible. Our goal is to provide every Russian patient with innovative, highly effective and affordable drugs as soon as possible."